Continuing Pharmacy Education / ACPE Topic Designation / Pain Management: Relief Reimagined: Pain Strategies for Patients Battling Opioid Use Disorder (OUD)
Please use this button to register in our system as a new user, or to purchase a CE Activity.
For free CE's, returning users can simply click the "TAKE TEST/EVALUATION" button on the right.
Please use this button when you have completed the CE Activity and are ready to take the quiz and complete the evaluation.

Pain Management: Relief Reimagined: Pain Strategies for Patients Battling Opioid Use Disorder (OUD)

Learning Objectives

 

After completing this continuing education activity, pharmacists and pharmacy technicians will be able to

•        DESCRIBE pathophysiology of pain, OUD, and how both interact.
•        EXPLAIN OUD prevalence, risk factors, and common etiologies.
•        DISCUSS treatment strategies for pain management in those with OUD.

 

Release Date:

Release Date:  May 8, 2025

Expiration Date: May 8, 2028

Course Fee

Pharmacists:

Free until 7/31/2025

then$7

Pharmacy Technicians:

Free until 7/31/2025

then $4

There is no grant funding for this CE activity

ACPE UANs

Pharmacist: 0009-9999-25-06-H08-P

Pharmacy Technician: 0009-9999-25-006-H08-T

Session Codes

Pharmacist: 25UC06-ABC24

Pharmacy Technician: 25UC06-XYZ48

Accreditation Hours

0.5 hours of CE

Accreditation Statements

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ACPE UAN 0009-9999-25-006-H08-P/T  will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

 

Disclosure of Discussions of Off-label and Investigational Drug Use

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Faculty

 

Molly Csere, PharmD
PGY-1 Resident
UConn Health Center
Farmington, CT

Megan Mitchell, PharmD, MS
Pharmacy Clinical Coordinator Pain Management and Palliative Care
UConn Health Center
Farmington, CT

Mariam Zedan, PharmD,
PGY-1 Resident
UConn Health Center
Farmington, CT

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

Drs. Csere, Mitchell and Zedan have no relationships with ineligible companies and therefore have nothing to disclose.

 

CONTENT

Content

Download PDF of Handouts

Download CE Activity

Pharmacist Post Test (for viewing only)

CE Title: Pain Management: Relief Reimagined - Pain Strategies for Patients Battling Opioid Use Disorder (OUD)
Pharmacist Post-Test

Learning Objectives:
1. Explain OUD prevalence, risk factors, and common etiologies
2. Describe pathophysiology of pain, OUD, and how both interact
3. Discuss treatment strategies for pain management in those with OUD

1. Which of the following is considered a risk factor for Opioid Use Disorder?
a. Previous diagnosis of bipolar disorder
b. Family history of migraines
c. Social norms discouraging substance use

2. Which of the following is most likely to occur with continued use of opioids?
a. Deregulation of pain, touch, and temperature receptors
b. Physical and chemical changes in the brain
c. Strengthening pain pathways in the brain

3. Which medication has the highest receptor binding affinity (lowest Ki value)?
a. Oxycodone
b. Fentanyl
c. Buprenorphine

4. Which of the following risks increase when initiating opioid detoxification without initiating a medication for OUD?
a. Resumed drug use
b. Financial burden
c. Social alienation

5. Which of the following receptors is most associated with opioid pathophysiology?
a. Beta-1
b. Mu
c. Alpha

6. Compared to the duration of occupation at the receptor level, the duration of analgesia of buprenorphine is:
a. Longer
b. The same
c. Shorter

Pharmacy Technician Post Test (for viewing only)

Pharmacy Technician Post-Test
Learning Objectives:
1. Explain OUD prevalence, risk factors, and common etiologies
2. Describe pathophysiology of pain, OUD, and how both interact
3. Discuss treatment strategies for pain management in those with OUD

1. Patients with Opioid Use Disorder have an increased risk of:
a. Falls and drowning
b. Community-acquired pneumonia
c. Road traffic tickets

2. Which of the following senses are involved in the pathways that opioids block?
a. Taste
b. Temperature
c. Balance

3. Which of the following medication options for OUD is available in a sublingual formulation?
a. Buprenorphine
b. Methadone
c. Naltrexone

4. Which of the following risks increase when initiating opioid detoxification without starting a medication for OUD?
a. Resumed drug use
b. Financial burden
c. Social alienation

5. Which of the following receptors is most associated with opioid pathophysiology?
a. Beta-1
b. Mu
c. Alpha

6. Compared to the duration of occupation at the receptor level, the duration of analgesia of buprenorphine is:
a. Longer
b. The same
c. Shorter